We established an ex vivo pipeline for cancer drug sensitivity screening by adopting our previously reported culture set‐up to ensure MM cell survival, followed by CD138+ MM cell isolation at 48 h (Fig. 1A i–ii). This evidence concerns the gene SDC1 and Miyoshi myopathy.